Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 4
2006 1
2007 1
2008 5
2009 11
2010 18
2011 21
2012 44
2013 64
2014 82
2015 67
2016 106
2017 142
2018 144
2019 177
2020 187
2021 228
2022 233
2023 179
2024 56

Text availability

Article attribute

Article type

Publication date

Search Results

1,532 results

Results by year

Filters applied: . Clear all
Page 1
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Sandborn WJ, et al. N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910. N Engl J Med. 2017. PMID: 28467869 Free article. Clinical Trial.
We further evaluated the efficacy of tofacitinib as induction and maintenance therapy. METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis. ...Across all three trials, adju …
We further evaluated the efficacy of tofacitinib as induction and maintenance therapy. METHODS: We conducted three phase 3, randomize …
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Berekmeri A, et al. Expert Rev Clin Immunol. 2018 Sep;14(9):719-730. doi: 10.1080/1744666X.2018.1512404. Expert Rev Clin Immunol. 2018. PMID: 30118353 Free article. Review.
Tofacitinib efficacy was demonstrated in PsA by the OPAL Broaden and OPAL Beyond phase-III studies, and received FDA and EMA approval. ...Tofacitinib and other JAK inhibitors show potential to broaden the treatment options in PsA and other inflammatory conditions... …
Tofacitinib efficacy was demonstrated in PsA by the OPAL Broaden and OPAL Beyond phase-III studies, and received FDA and EMA approval …
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Kristensen LE, et al. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17. Ann Rheum Dis. 2023. PMID: 36931693 Free PMC article. Clinical Trial.
CONCLUSIONS: This posthoc analysis of ORAL Surveillance identified two tofacitinib subpopulations with different relative risk versus TNFi. High risk was confined to patients defined by distinct risk factors age 65 years or smoking, and these differentiating risk factors a …
CONCLUSIONS: This posthoc analysis of ORAL Surveillance identified two tofacitinib subpopulations with different relative risk versus …
Pharmacology and safety of tofacitinib in ulcerative colitis.
López-Sanromán A, Esplugues JV, Domènech E. López-Sanromán A, et al. Gastroenterol Hepatol. 2021 Jan;44(1):39-48. doi: 10.1016/j.gastrohep.2020.04.012. Epub 2020 Aug 20. Gastroenterol Hepatol. 2021. PMID: 32829958 Free article. Review. English, Spanish.
The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory diseases with immune base. Tofacitinib is one of these inhibitors targeting JAK1 and JAK3, and its efficacy has been demonstrated in the treatment of moderate to severe ulcerative col …
The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory diseases with immune base. Tofacitinib is o …
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS. Mease P, et al. N Engl J Med. 2017 Oct 19;377(16):1537-1550. doi: 10.1056/NEJMoa1615975. N Engl J Med. 2017. PMID: 29045212 Free article. Clinical Trial.
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. ...The rate of adverse events through month 12 was 66% in the 5-mg tofacitinib group, 71% in the 10-mg tofacitinib group, 72% in th …
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. ...Th …
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators. Fleischmann R, et al. N Engl J Med. 2012 Aug 9;367(6):495-507. doi: 10.1056/NEJMoa1109071. N Engl J Med. 2012. PMID: 22873530 Free article. Clinical Trial.
METHODS: In this phase 3, double-blind, placebo-controlled, parallel-group, 6-month study, 611 patients were randomly assigned, in a 4:4:1:1 ratio, to 5 mg of tofacitinib twice daily, 10 mg of tofacitinib twice daily, placebo for 3 months followed by 5 mg of tofa …
METHODS: In this phase 3, double-blind, placebo-controlled, parallel-group, 6-month study, 611 patients were randomly assigned, in a 4:4:1:1 …
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. Traves PG, et al. Ann Rheum Dis. 2021 Jul;80(7):865-875. doi: 10.1136/annrheumdis-2020-219012. Epub 2021 Mar 19. Ann Rheum Dis. 2021. PMID: 33741556 Free PMC article.
OBJECTIVE: Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity. Filgotinib was compared with baricitinib, tofacitinib and upadaciti …
OBJECTIVE: Janus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, p …
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. Sandborn WJ, et al. Clin Gastroenterol Hepatol. 2022 Aug;20(8):1821-1830.e3. doi: 10.1016/j.cgh.2020.10.038. Epub 2020 Oct 27. Clin Gastroenterol Hepatol. 2022. PMID: 33127596 Free article. Clinical Trial.
BACKGROUND & AIMS: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). ...CONCLUSIONS: Overall, the majority of patients achieved a clinical response after 8 or 16 weeks' induction therapy with tofacitinib …
BACKGROUND & AIMS: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). .. …
JAK1 inhibition and inflammatory bowel disease.
Harris C, Cummings JRF. Harris C, et al. Rheumatology (Oxford). 2021 May 5;60(Supple 2):ii45-ii51. doi: 10.1093/rheumatology/keaa896. Rheumatology (Oxford). 2021. PMID: 33950226 Free PMC article. Review.
As our understanding of the pathogenesis of IBD evolves, new therapeutic targets are being identified. The JAK-STAT pathway has been extensively studied. Tofacitinib, a JAK1 inhibitor, is now licensed for use in the induction and maintenance of ulcerative colitis and there …
As our understanding of the pathogenesis of IBD evolves, new therapeutic targets are being identified. The JAK-STAT pathway has been extensi …
Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial.
Khanna D, Padilla C, Tsoi LC, Nagaraja V, Khanna PP, Tabib T, Kahlenberg JM, Young A, Huang S, Gudjonsson JE, Fox DA, Lafyatis R. Khanna D, et al. JCI Insight. 2022 Sep 8;7(17):e159566. doi: 10.1172/jci.insight.159566. JCI Insight. 2022. PMID: 35943798 Free PMC article. Clinical Trial.
BACKGROUNDSystemic sclerosis (SSc) is an autoimmune, connective tissue disease characterized by vasculopathy and fibrosis of the skin and internal organs.METHODSWe randomized 15 participants with early diffuse cutaneous SSc to tofacitinib 5 mg twice a day or matching place …
BACKGROUNDSystemic sclerosis (SSc) is an autoimmune, connective tissue disease characterized by vasculopathy and fibrosis of the skin and in …
1,532 results